Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1588576 | 0.98 | HTR2A (0.40) | HTR2CHTR2ADRD2SLC6A2SLC6A4 | |
| SCHEMBL19828185 | 0.87 | SIGMAR1 (0.33) | HTR2CHTR2ADRD2SIGMAR1HTR2B | |
| SCHEMBL29793198 | 0.87 | SIGMAR1 (0.33) | HTR2CHTR2ADRD2SIGMAR1HTR2B | |
| SCHEMBL30291391 | 0.82 | SIGMAR1 (0.38) | HTR2CHTR2ADRD2SIGMAR1HTR2B | |
| SCHEMBL3400338 | 0.79 | — | — | |
| SCHEMBL12017681 | 0.76 | HTR2A (0.47) | HTR2CHTR2ADRD2SLC6A2SLC6A4 | |
| SCHEMBL44425 | 0.74 | HTR2A (0.55) | HTR2CHTR2ADRD2SLC6A2SLC6A4 | |
| SCHEMBL30676406 | 0.74 | HTR2A (0.55) | HTR2CHTR2ADRD2SLC6A2SLC6A4 | |
| SCHEMBL22507670 | 0.74 | CA1 (0.32) | SIGMAR1 | |
| SCHEMBL12964445 | 0.73 | CYP2D6 (0.44) | SIGMAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-8664216-B2 | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664216-B2 | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2356123-B1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2012-10-03 | — | — | EP | disclosed |
| EP-2356123-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2010054961-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| WO-2007057775-A1 | SPIROPIPERIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| US-5807871-A | PSYCHOLOGICAL DISORDERS, ALZHEIMER OR PARKINSON DISEASE | H. LUNDBECK A/S (DK) | 1998-09-15 | — | — | US | disclosed |
| EP-0593511-B1 | PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT | LUNDBECK & CO AS H (DK) | 1998-09-02 | — | — | EP | disclosed |
| EP-0518805-A1 | Piperidine derivatives | H. LUNDBECK A/S (DK) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | AVPR1A, OXTR, AVPR1B | HTR2C 114/4885HTR2A 68/4885DRD2 141/4885 |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | HTR2C 284/4885HTR2A 889/4885DRD2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.